In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu lead a discussion on the recently completed ASCO 2023 meeting that included presentation of the new overall survival data from the ADAURA trial as well as the New England Journal of Medicine publication on data from KEYNOTE 671.
WCLC 2023 is a global, multi-disciplinary meeting designed for physicians, nurses, clinicians, researchers, scientists, survivors and advocates. This year, the meeting rotates to Singapore and Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by the meeting's three co-chairs for a wide-ranging interview about how attendees can make the most out of their experience during IASLC's flagship annual conference.
LCC in Polish: Overcoming Barriers to Lung Cancer Therapy in Poland This special Polish-language episode of Lung Cancer Considered focuses on the unique challenges facing clinicians, researchers, and patients in Poland. The podcast also focuses on how physicians help patients overcome barriers to treating lung cancer. Host: Dr Anna Wrona, Department of Oncology and Radiotherapy, Medical University of Gdansk Guests: Professor Rafał Dziadziuszko, M.D., Ph.D., Head, Department of Oncology & Rad...
In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ROS+1 Fusions in NSCLC, including diagnosis, treatment and new exciting research coming down the pipeline. Her guests are: Dr. Lorenza Landi, Director of Clinical Trials Unit: Phase 1 and Precision Medicine at the National Cancer Institute Regina Elena in Rome. Dr. Landi has extensive experience and is interested in targeted therapy in lung cancer with a focus on ALK, HER-2/EGFR positive and ROS+1 lung cancer. Dr. Shiri...
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on EGFR NSCLC and transformation to small cell lung cancer, a relatively new finding since the introduction of targeted therapy. Guests are: Dr. Shigeki Umemura Dr. Shigeki Umemura is from the Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. His interests include targeted therapy in lung cancer, including genomic profiling of small cell lung cancer, evaluation of tumor microe...
Lung Cancer Considered hosts Dr. Narjust Flores and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial. ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR positive NSCLC. While we have seen targeted therapy in this space ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez interviews Dr. Emily Stone, the new editor of JTO Clinical and Research Reports. The podcast will focus on her article “Building on a Legacy”.
Host Dr. Alfredo Addeo, Senior Oncologist, Geneva University Hospital, in Geneva, Switzerland moderates a special French-language episode of Lung Cancer Considered focusing on managing locally advanced NSCLC. The guests for this special podcast are Dr. Cecile Le Pechoux, Radiation Oncologist at Department of Radiation Oncology Unit of Thoracic Oncology, Soft Tissue Sarcomas and Mesenchymal Tumour, and Dr. Jonathan Spicer, Associate Professor, Division of Thoracic Surgery. Director, McGill Thorac...
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Copenhagen. Host Dr. Stephen Liu, Dr. Heather Wakelee and Dr. Paul Van Schil discuss the important research presented at the meeting.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a new Virtual Tumor Board on EGFR mutant NSCLC and acquired resistance. Dr. Liu is joined by two thoracic medical oncologists who are both global experts in targeted therapy.
IASLC - LCC in Italian: Updates in Resectable NSCLC by IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a conversation about small cell lung cancer and previews the upcoming IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer in April which is focused on both preclinical and clinical advances in small cell lung cancer research. Joining the conversation are Alvaro Quintanal-Villalonga, PhD., from the Rudin Lab at Memorial Sloan Kettering Cancer Center in New York, and Kate Sutherland, PhD., from the Walter and Eliza Hall Ins...
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation about the use of consolidated radiation in early-stage small cell lung cancer. Joining the debate are Dr. Lawrence Einhorn from the Indiana University School of Medicine and Dr. Charles Simone from Memorial Sloan Kettering.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a recap of the recent IASLC meeting, Targeted Therapies for Lung Cancer, or TTLC23 --a member-favorite, a relatively smaller meeting known for its fast pace and its breadth of content. Guests include, the two co-chairs of the meeting: Dr. Charu Aggarwal, thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pen...
In this Virtual Tumor Board episode of Lung Cancer Considered, host Dr. Stephen Liu and his guests discuss the dynamic topic of managing resectable stage III NSCLC. Joining him are: Dr. Isabelle Schmitt-Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surger...
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a specific subset of lung cancer: EGFR exon 20 insertion NSCLC. Joining the podcast are distinguished panel of clinicians and lung cancer advocates: Dr. Rosario Garcia Campelo, the Head of Medical Oncology and the Thoracic Tumor Unit Chair at the University Hospital A Coruna, Spain. Marcia Horn, executive director of the Exon 20 Group and CEO of ICAN, the International Cancer Advocacy Network. Yonsei University...
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pipeline. Podcast guests are: Dr. Justin Gainor, the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. His major re...
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a conversation on KRAS G12C mutation. Joining the podcast are Dr. Melissa Johnson, the Program Director of Lung Cancer Research at the Sarah Cannon Research Institute and Dr. Ferdinandos Skoulidis, an Associate Professor at the University of Texas MD Anderson Cancer Center.
The Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January. To provide a summary of key findings from the meeting, Lung Cancer Considered host Dr. Narjust Florez interviewed two prominent oncologists from South America: Dr. Clarissa Mathias, Dr. Mathias is a medical oncologist and director of NOB/Oncoclinicas in Brazil. She is a member of the ASCO International Quality Steering Group and Lung cancer committee. Dr. Mathias served on the IASLC board and has led many ...
On January 26, 2023, the US FDA granted approval of pembrolizumab, an anti-PD-1 antibody, as an adjuvant therapy for patients with resected NSCLC. In this episode of Lung Cancer Considered host Dr. Stephen Liu leads a discussion on this approval with two thoracic medical oncologists with extensive expertise in this space: Dr. Jamie Chaft, an Associate Attending at Memorial Sloan Kettering Cancer Center, where she is the Director of Early Stage Lung Cancer Research, chair of the adjuvant nivoluma...
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the er...
In a special episode of Lung Cancer Considered focusing on lung cancer in Brazil, host Dr. Clarissa Mathias, medical oncologist at Oncoclinicas Bahia and Hospital Santa Izabel, is joined by Dr. Ticiana Leal, associate professor, Department of Hematology & Oncology and director of Thoracic Medical Oncology, Winship Cancer Institute, Emory University and Dr. Carlos Gil Ferreira, president of Instituto Oncoclinicas and chief medical officer – Oncoclínicas.
Host Dr. Narjust Florez engages with three leading lung cancer patient advocates on the importance of patient advocacy groups, how these were formed, challenges when managing large patient advocacy groups and the future of patient advocacy in lung cancer. Janet Freeman-Daily is a cancer patient research advocate and activist who translates the experience and science of cancer for others. She was diagnosed with advanced lung cancer in 2011 and metastatic ROS1+ lung cancer in 2012. She collaborate...
Radon exposure is a known risk factor for lung cancer yet it does not garner as much attention as other risk factors. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses radon, its impact on lung cancer diagnosis, new research covering radon and strategies to improve our patients and the general population's exposure to this radioactive gas. Her guest is Dr. Hina Khan, thoracic medical oncologist at the Lifespan Cancer Center and an assistant professor at The Warren Alpe...
Radiologists play central roles in the detection of lung cancer, in assessing response to therapy and relapse of disease and increasingly, interventional radiologists are involved with tissue sampling and lung cancer treatment. In this episode of Lung Cancer Considered, host Dr. Stephen Liu interviews two noted radiologists--Dr. Carole Ridge and Dr. Florian Fintelmann. Dr. Ridge is a consultant radiologist at Royal Brompton Hospital and a Senior Clinical Research Fellow at Imperial College Londo...
This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla...
In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in Israel, spoken in Hebrew. Host Dr. Alona Zer, Head of the Department of Medical Oncology at the Rambam Health Care Campus, Haifa, Israel welcomes guests Dr. Jair Bar, Deputy Director, Institute of Oncology at Chaim Sheba Medical Center and Associate Professor of Oncology, School of Medicine at Tel Aviv University and Dr. Nir Peled, Head, the Cancer Institute at Shaare Zedek Medical...
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and invited guests to discuss the IASLC Asian Conference on Lung Cancer (ACLC) held in Japan and the ESMO Asia meeting held in Singapore. Guests include Dr. James Yang, director and Professor of the Graduate Institute of Oncology at the National Taiwan University and the director of the Department of Oncology at the National Taiwan University Hospital, Dr. Thanyanan Baisamut, consultant in the Division of Medical Oncology at Ramathi...
In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in the Middle East (North Africa), spoken in Arabic. Host Dr. Nagla Karim, MD, PHD, Director of the Phase I Program at the Inova Schar Cancer Institute welcomes guests Dr. Abdelrahman Mohamed, MD, Head of Thoracic Surgery, NCI at Cairo University and Dr. Houssein Abdul Sater, MD, Physician Scientist, Immuno-Oncology and Regional Research Director, Cancer Institute at Cleveland Clinic ...
This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Regu...
